Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

Patent metadata

Field	Value
Publication number	US-9168249-B2
Application number	US-201514613367-A
Country	US
Kind code	B2
Filing date	Feb 4, 2015
Priority date	Oct 26, 2006
Publication date	Oct 27, 2015
Grant date	Oct 27, 2015

Abstract

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

First claim

The invention claimed is:

1. A method of treatment of a cardiovascular disease, cardiac insufficiency, anemia, a chronic kidney disease or renal insufficiency comprising administering to a human or animal in need thereof an active amount of a compound of formula (I)

in which
R 1 represents a heteroaryl group of the formula

wherein
* denotes the linkage point with the dihydropyrazolone ring
and
R 4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxymethyl, (C 1 -C 4 )-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C 1 -C 4 )-alkoxycarbonyl,

R 2 represents a heteroaryl group of the formula

wherein
# denotes the linkage point with the dihydropyrazolone ring
and
R 6 , R 6A and R 6B are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C 1 -C 6 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 6 )-alkoxy, trifluoromethoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl and 4- to 6-membered heterocycloalkyl, wherein
 (C 1 -C 6 )-alkyl in its turn can be substituted by hydroxyl, (C 1 -C 4 )-alkoxy or amino
 and
 4- to 6-membered heterocycloalkyl in its turn can be substituted once or twice in an identical or different manner by fluorine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, hydroxyl, (C 1 -C 4 )-alkoxy, oxo, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl and/or (C 1 -C 4 )-alkoxycarbonyl,

and
R 3 represents hydrogen,
and their salts, solvates and solvates of the salts.

2. The method of treatment of claim 1 , wherein the compound of formula (I) is 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]-1,2-dihydro-3H-pyrazol-3-one having the following formula

and its salts, solvates and solvates of the salts.

Assignees

• Bayer Ip Gmbh

Inventors

• Thede Kai
• Flamme Ingo
• Oehme Felix
• Ergüden Jens-Kerim
• Stoll Friederike
• Schuhmacher Joachim
• Wild Hanno
• Kolkhof Peter
• Beck Hartmut
• Keldenich Jörg
• Akbaba Metin
• Jeske Mario

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title